NCT06276361View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 26, 2023

Primary Completion Date

July 7, 2025

Study Completion Date

July 7, 2025

Conditions

Schizophrenia

Interventions

DRUG

Oral risperidone; QUAR F1/2, Dose 1 - Gluteal

Dose level 1

DRUG

Oral risperidone; QUAR F1/2, Dose 2 - Gluteal

Dose level 2

DRUG

Oral risperidone; QUAR F1/2, Dose 3 - Gluteal

Dose level 3

DRUG

Oral risperidone; QUAR F1/2, Dose 3 - Deltoids

Dose level 3

Trial Locations (1)

Unknown

Investigational Site, Amman

All Listed Sponsors

lead

Rovi Pharmaceuticals Laboratories

INDUSTRY

NCT06276361 - Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia | Biotech Hunter | Biotech Hunter